biotech

article placeholder

Have You Heard. February 2010

WA biotech emerging?

WA biotech company Resonance Health (ASX: RHT) has finally moved into the black with its image analysis technology, primarily in the form of FerriScan® quantitative MRI image analysis, developed to assess the degree of liver iron overload in haemochromatosis. Since 2005-06 (when the company underwent a share consolidation and major belt tightening), revenues from FerriScan have increased from $0.3m to $2.3m and during 2008-09 the company reported its first profit of $617k. The company is looking to apply its technology to the diagnosis of liver fibrosis (as an alternative to liver biopsy) in a broader range of liver diseases and to a much wider market, all by 2012. The inability of the test to make it onto the MBS Schedule has been a major revenue block but regulatory approval by the FDA and other European agencies has seen these markets begin to open. Lisa Dunne, Managing Director since 2003, has been a driving force along with Perth Radiological Clinic's Dr Martin Blake, UWA scientist Prof Timothy St Pierre, board chairman and biotech investor Dr Stewart Washer and major shareholder Mr Simon Panton.

Vulva awareness

Health professionals are increasingly asked to dovetail in with ‘illness/health days' or ‘health awareness weeks', dreamt up by clever marketing people who flog red noses, moustaches, pink ribbons, etc to create awareness and raise....

... Read More...
article placeholder

June 2008

Cloning battle lost

Health Minister Jim McGinty says the defeat of WA's cloning bill, which would have opened up new fields of medical research in this state, is an embarrassing "slap in the face to Western Australia's scientific community." The cloning bill would have brought WA into line with other states by allowing excess embryos created through fertilisation to be used for medical research. However, conservatives from both political parties defeated the bill by 18 votes to 15 in the upper house. With the bill defeated, the short to medium term future of embryo research in WA is bleak, although with an imminent election, the bill could potentially be resurrected within 12 months.

Gray case over... almost

We've lost count of the number of rounds the three-way battle between Dr Bruce Gray, UWA, and Sirtex has lasted, but the resilient Bruce has struck a TKO on the university that originally sponsored his commercially successful research by winning a protracted court case. The fight has centred on Dr Gray's development of microspheres to fight liver cancer, which has been commercialised into multi-million dollar medical technology. The technology was developed while he worked at UWA. The win creates a dangerous precedent in that other researchers could commercialise their university-sponsored discoveries unless they have a contract stating otherwise. UWA has confirmed it will be appealing the decision, so another costly and complicated round of legal manoeuvring is on the cards.

Advance hits trouble

Just a month after offloading Cottman Australia for a tidy $8m, Advance Healthcare Group (AHG) has asked its major creditor, Fulcrum Equity, to place AHG and its subsidiaries into administration ...

... Read More...
article placeholder

October 2007

Payout for "hostile" medico's sacking

The Human Rights and Equal Opportunity Commission has recommended that Derbarl Yerrigan Health Service (DYHS) apologise and pay compensation to Dr Julie Copeman for terminating her employment at a Perth clinic in 2004, allegedly for lobbying about colleagues' workplace conditions as an AMA rep. They found DYHS was frustrated that Dr Copeman had discussed her colleagues' complaints in a forceful, open manner that was "interpreted as being hostile". The Commission recommended DYHS pay Dr Copeman $76,185 compensation for emotional hurt and lost income.

Primary scuttle Symbion/Healthscope merger

Primary Health Care has used its recently acquired 20% stake in Symbion to scuttle the long-expected Symbion/Healthscope merger. Although 99.2% of voters (representing 73.9 % of total shares) were in favour, the requirement to meet a share vote of 75% was stymied by Primary. Healthscope and Symbion are now "discussing other options".

Addiction Medicine fellowships

Tony Abbott has signed off on Addiction Medicine being recognised as a specialty...

... Read More...